AiCuris Initiates Clinical Development of AIC499


AiCuris Anti-infective Cures GmbH, a leading company in the discovery and development of drugs against infectious diseases, today announced the start of a new clinical program with AIC499, an innovative beta-lactam antibiotic against a broad range of multidrug-resistant (MDR) Gram-negative bacteria in complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). Read the full press release below.

Read press release

First Patients in ASPIRE-SSI


COMBACTE-NET's ASPIRE-SSI study team achieved the first subject enrolled at the University Medical Center Utrecht, Netherlands on December 20, 2016 – within 5 months of protocol approval.

Read full article

Involving Patients and the Public in Antimicrobial Research: Are We Missing Something Important?


In recent years Interest has rapidly grown in patient and public involvement in research (PPI). Such involvement in health research has been advocated both on ethical grounds and that it improves the quality of research.

Read full article

CLIN-Net and LAB-Net Country Visit Romania


This year’s series of COMBACTE’s country visits kicked off with Romania on 11th-12th January. No less than six hospitals and laboratories in Bucharest were visited. Andrei Ursache, the CLIN-Net National Coordinator in Romania, accompanied the CLIN-Net and LAB-Net representatives during their visit.

Read full article

COMBACTE Investigators Meeting at SRLF Congress 


Between January 11th and 13th 2017, COMBACTE took part in SRFL’s Reanimation 2017 Congress in Paris, France. During the congress, the COMBACTE booth provided information on current and future clinical research projects to emergency physicians, infectiologists and intensive care doctors. Next to that, a breakout session and an Investigator Meeting took place.

Read full article

Check out the newsroom

Upcoming events


 Face to Face GCP Training

1 day
Sofia, Bulgaria


4 days
Vienna, Austria

COMBACTE General Assembly

3 days
Brussels, Belgium
Got great ideas for the newsletter?
Contact the PMO

This research project receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115523 | 115620 | 115737 resources of which are composed of financial contribution from the European Union Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution.